SCHEMBL19927899

SCHEMBL19927899

CC(N)CCC(C)NC(=O)C1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 3/20 0.43
ACACB O00763 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HSD17B10 Q99714 1/20 0.42
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
PSMB5 P28074 1/20 0.40
RECQL P46063 1/20 0.40
EPHX1 P07099 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27639742 0.83 GAA (0.51) GAACYP2C9CYP2C19LMNAHPGD
SCHEMBL24568205 0.81 GAA (0.47) GAACYP2C9CYP2C19LMNAHPGD
SCHEMBL15715059 0.81 GAA (0.49) GAACYP2C9CYP2C19LMNAHPGD
SCHEMBL27639734 0.80 NAAA (0.53) GAACYP2C9CYP2C19LMNAHPGD
SCHEMBL23253780 0.80 GAA (0.46) GAACYP2C9CYP2C19LMNAHPGD
SCHEMBL10308293 0.79 GAA (0.61) GAACYP2C9CYP2C19LMNAHPGD
SCHEMBL24567736 0.79 GAA (0.61) GAACYP2C9CYP2C19LMNAHPGD
SCHEMBL6887946 0.78 HDAC8 (0.50) GAALMNAHPGDSMN1; SMN2HDAC8
SCHEMBL10307933 0.77 PSMB5 (0.52) GAACYP2C9CYP2C19LMNAHPGD
Hydrochloric Acid SCHEMBL20538683 0.77 HDAC8 (0.48) GAALMNAHPGDSMN1; SMN2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654832-B2 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof SAMUMED, LLC (US) 2020-05-19 US disclosed
US-20190352279-A1 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-11-21 US disclosed
US-9908867-B2 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof SAMUMED, LLC (US) 2018-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352279-A1 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A GAA 2514/4885CYP2C9 2094/4885CYP2C19 2424/4885
US-10654832-B2 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof WNT1, WNT3, WNT3A GAA 2514/4885CYP2C9 2094/4885CYP2C19 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.